Evidence map›Paper›PMID 23776605›Full record

ArticlePloS one2013

Deficiency of Leishmania phosphoglycans influences the magnitude but does not affect the quality of secondary (memory) anti-Leishmania immunity.

Dong Liu, Ifeoma Okwor, Zhirong Mou, Stephen M Beverley, Jude E Uzonna

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Selective activity of Oleanolic and Maslinic Acids on the Amastigote form ofIranian journal of pharmaceutical research : IJPR · 2017
    Article
  3. Article
  4. An overview on Leishmania vaccines: A narrative review article.Veterinary research forum : an international quarterly journal · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Dong LiuDepartment of Immunology, University of Manitoba, Winnipeg, MB, Canada.
Ifeoma Okwor
Zhirong Mou
Stephen M Beverley
Jude E Uzonna
University of Manitoba · CAWashington University in St. Louis · US

Funding

GLYCOSYLATION MUTANTS OF LEISHMANIAR01AI031078 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1992 to 2019
$11.4M
CIHRNIAID NIH HHS AI31078NIAID NIH HHS R01 AI031078
6 · The paper itself

Abstract

Despite inducing very low IFN-γ response and highly attenuated in vivo, infection of mice with phosphoglycan (PG) deficient Leishmania major (lpg2-) induces protection against virulent L. major challenge. Here, we show that mice infected with lpg2- L. major generate Leishmania-specific memory T cells. However, in vitro and in vivo proliferation, IL-10 and IFN-γ production by lpg2- induced memory cells were impaired in comparison to those induced by wild type (WT) parasites. Interestingly, TNF recall response was comparable to WT infected mice. Despite the impaired proliferation and IFN-γ response, lpg2- infected mice were protected against virulent L. major challenge and their T cells mediated efficient infection-induced immunity. In vivo depletion and neutralization studies with mAbs demonstrated that lpg2- L. major-induced resistance was strongly dependent on IFN-γ, but independent of TNF and CD8(+) T cells. Collectively, these data show that the effectiveness of secondary anti-Leishmania immunity depends on the quality (and not the magnitude) of IFN-γ response. These observations provide further support for consideration of lpg2- L. major as a live-attenuated candidate for leishmanization in humans since it protects strongly against virulent challenge, without inducing pathology in infected animals.

Indexed as

AnimalsCD8-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayFemaleInterferon-gammaInterleukin-10LeishmaniaLeishmania majorMiceMice, Inbred BALB CMice, Inbred C57BLTumor Necrosis Factor-alphaInterferon-gammaInterleukin-10Tumor Necrosis Factor-alpha

Identifiers

PMID23776605
PMCPMC3679009
OpenAlexW2080313856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.